Trans-cinnamaldehyde

PreclinicalSmall molecule

AAalborg University

Trans-cinnamaldehyde is one of 5 small molecule programs targeting Desensitization. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DesensitizationUnknown status

DesensitizationPreclinical

Unknown status

Competition

Competitive Landscape

4 competitors in Desensitization

#DrugCompanyPhaseTrials

Nulojix

Bristol-Myers Squibb

Phase 2

2 2

DARZALEX FASPRO

Johnson & Johnson

Phase 2

1 3

Kyprolis

VVirionyx Corporation Limited

Phase 2

3 4

L-Menthol

RRegion Skane

Preclinical

1 5

Trans-cinnamaldehyde

AAalborg University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Desensitization1 trial

Desensitization of Nociceptive Afferents by Application of Topical Capsaicin, Trans-cinnamaldehyde and L-menthol

Unknown status·—·N/A·NCT03132142·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Trans-cinnamaldehyde. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Trans-cinnamaldehyde compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Trans-cinnamaldehyde. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aalborg University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAalborg University

Trans-cinnamaldehyde

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Desensitization1 trial

References

Drug Info

Quick Facts

Related News